Previous 10 | Next 10 |
Axonics Modulation Technologies (NASDAQ: AXNX ) initiated with Overweight rating at Piper Jaffray. More news on: Axonics Modulation Technologies, Inc., Homology Medicines, Inc., Sarepta Therapeutics, Inc., Healthcare stocks news, Stocks on the move, , Read more ...
Takeda Pharmaceutical Company (NYSE: TAK ) H1 results (billion yen): More news on: Takeda Pharmaceutical Company Limited, Healthcare stocks news, Earnings news and commentary, Read more ...
FY2019 H1 revenue 1660.2 billion yen, up +88.5% versus prior year mainly due to acquisition of Shire and solid performance of 14 global growth brands Strong core operating profit * of 541.6 billion yen, up +155.5% versus FY2018 H1 and Underlying Core Operating Profit Margi...
LEXINGTON, Mass. , Oct. 28, 2019 /PRNewswire/ -- Takeda Pharmaceuticals U.S.A. , Inc., ("Takeda") ( TSE:4502/NYSE:TAK ) announced today that Budesonide Oral Suspension (BOS), its investigational therapy for the treatment of eosinophilic esophagitis (EoE), achieved co-primary and k...
Based on positive data from a mid-stage study, Takeda Pharmaceutical Company (NYSE: TAK ) has secured a global license to COUR Pharmaceutical Development Company's CNP-101 (TAK-101), an intravenously administered immune-modifying nanoparticle containing gliadin proteins, for the potential ...
− Late-breaking data presented from a Phase 2a trial at UEG Week 2019, Barcelona, Spain, highlights potential of investigational medicine to prevent gluten induced immune activation in patients with celiac disease − Takeda acquires exclusive global license to investiga...
- Latest real-world data presented at UEG Week 2019 complements the extensive body of clinical evidence for the gut-selective biologic vedolizumab in biologic-naïve patients with moderately to severely active ulcerative colitis or Crohn’s disease Takeda Pharma...
Phathom Pharmaceuticals ( PHAT ) has filed a preliminary prospectus for a 7.9M-share IPO at $18 - 20 per share. More news on: Phathom Pharmaceuticals, Takeda Pharmaceutical Company Limited, Healthcare stocks news, IPO News, Read more ...
On a strict party line basis, the U.S. House of Representatives' Education and Labor Committee voted 27-21 backing Speaker Nancy Pelosi's drug pricing bill (H.R. 3). All 27 Dems voted in favor and all 21 GOP members voted against. More news on: Pfizer Inc., Merck & Co., Inc., Bristol...
Thinly traded nano cap Protalix BioTherapeutics (NYSEMKT: PLX ) is up 18% premarket on modest volume in reaction to 12-month data on pegunigalsidase alfa (PRX-102) from the first 16 Fabry subjects in the open-label Phase 3 BRIDGE switchover study. More news on: Protali...
News, Short Squeeze, Breakout and More Instantly...
Takeda Pharmaceutical Company Limited American Depositary Shares Company Name:
TAK Stock Symbol:
NYSE Market:
− ENTYVIO is Now Available in the U.S. in Both IV and Subcutaneous Administrations for Maintenance Treatment of Adults with Moderately to Severely Active Ulcerative Colitis or Crohn’s Disease Takeda ( TSE:4502/NYSE:TAK ) today announced that the U.S. ...
FY23 Investment Brings Program Total to Nearly $55 Million, Welcoming Eight New Grant Partners Company Continues to Advance Equity in Under-Resourced Communities with a Focus on Nutrition and STEM Education Takeda Publishes its Annual U.S. Community Impact Report Highlighting Prog...
2024-04-05 02:02:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...